condep1002
10/05/16 11:57
Todo
Foros
Blogs
Entidades
Productos
Expertos
Usuarios
Formación
Vídeos
Acceder
- Inicio
- Perfil de condep1002
- Participaciones
Participaciones del usuario condep1002
condep1002
10/05/16 10:54
Ha respondido al tema Farmas USA
Ir a respuesta
http://www.smarteranalyst.com/2016/05/06/h-c-wainwright-reiterates-buy-amarin-corporation-plc-adr-following-1q16-update/
http://www.marketbeat.com/stocks/NASDAQ/AMRN/
5/9/2016 HC Wainwright Reiterated Rating Buy $10.00
condep1002
25/01/16 19:19
Ha respondido al tema Farmas USA
Ir a respuesta
First, JELIS (53% RRR in the closest group to RI), CHERRY (plaque decrease) and multiple other studies that show incredible benefit of EPA. ZU posts new studies nearly daily that show multiple benefits. In order for RI to fail, all these must be false. That is impossible because they aren't related to each other. Trust me, I read more on EPA than I ever wanted to know about any drug. So based on this, I am convinced that V will decrease the rate of CVD. Let's get more specific.
I was fortunate that a very informative investor shared with me his calculations of multiple scenarios that could occur. Although his calculations are incredibly thorough, I realize it's not guaranteed to be 100% accurate because we don't have all the information, but this is the best there is, with the information that was made available publicly.
Using enrollment numbers, he created a matrix (it's not simple math): x axis - placebo rates, y axis RRR, inside the matrix are dates of when 967 and 1612 will occur. Again, this is based on enrollment numbers, placebo rate and RRR. So for example, this matrix shows that if placebo rate is 5.2 and RRR is 30%, #967 will occur on February xx.Important to remember, because we don't know the placebo rate, we can't use this to predict anything but we can use it to give is different possibilities, such as the example I just gave or if placebo rate is 5.6 and RRR is 40%, 967 will occur in February xx or if placebo rate is 4.9 and RRR is 8%, 967 occurred in November.
So there are many many possibilities but they can be easily narrowed down. The company said that interim
must occur in 2016 and final in 2017. With this rule in mind, intrerim must occur in January-February, with a slight chance for early March as well. Anything after that will not give enough for the remaining 645 events to occur.
condep1002
28/12/15 16:39
Ha respondido al tema Farmas USA
Ir a respuesta
Goldman & Company boosted its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 321.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The hedge fund owned 1,282,306 shares of the biopharmaceutical company’s stock after buying an additional 977,861 shares during the period. J. Goldman & Company’s holdings in Amarin Co. plc were worth $2,475,000 at the end of the most recent quarter
condep1002
26/12/15 13:48
Ha respondido al tema Abengoa levanta el vuelo
Ir a respuesta
No os preocupéis esta mañana me ha dicho que se prepara la GRAN COALICIÓN; PESOEMOS = PSOE+PODEMOS+IZQUIERDA UNDIDA+ E APOYO PUNTUAL DE NACIONALISTAS SECIONISTAS; y una de las condiciones que ha puesto SUSANA ES SALVAR A ABENGOA; esto se parece a la película "Salvar al soldado Rayan" ya ha muerto 3/4 partes de la empresa vamos a salvar la que queda para que la jerarquía andaluza permanezca; PARA GARANTIZARSE EL APOYO ANDALUZ, Aquí cada uno tendrá su parte ; creedme, cada uno sacara lo suyo , y adivináis de donde va a salir la pasta si....si... lo adivinasteis del bolsillo de los contribuyentes . Luego dentro de unos cuantos años ya veremos; alguno vendrá que tendrá que arreglarlo digo yo; si el barco llamado España no se hunde.
condep1002
11/12/15 13:45
Ha respondido al tema Farmas USA
There is no way WS can keep this down now. Its been a long haul,but its finally here.$$$$$$$$$$$$$
Ir a respuesta
condep1002
08/12/15 10:55
Ha respondido al tema Abengoa levanta el vuelo
Ir a respuesta
Mañana habrá acuerdo sobre la liquidez de la empresa; hay muchos intereses creados para que no se produzca la quiebra; las acciones probablemente tocaran fondo; pero la empresa seguirá funcionando; lo que esta claro que las acciones no valen casi nada, por no decir nada;
condep1002
04/12/15 20:50
Ha respondido al tema Farmas USA
Ir a respuesta
By: Accesswire
December 04, 2015 at 09:00 AM EST
Market Data on Movers and Shakers - Research on Medifast, Potbelly, Amarin and Idera Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Medifast Inc (NYSE: MED), Potbelly Corp (NASDAQ: PBPB), Amarin Corporation plc (NASDAQ: AMRN) and Idera Pharmaceuticals Inc (NASDAQ: IDRA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis
condep1002
01/12/15 23:28
Ha respondido al tema Farmas USA
Ir a respuesta
original
Traders are looking for Amarin to rally in coming weeks.
optionMONSTER's Heat Seeker monitoring system detected the purchase of more than 7,000 December 2.50 calls for $0.03 to $0.06 today. Volume surpassed open interest of 1,530 contracts, an indication that new money was put to work.
Long calls lock in the price where investors can buy stock, allowing them to profit from a rally with limited capital at risk. Their cheap cost can also generate significant leverage on a percentage basis if shares move in the right direction. (See our Coaching section)
AMRN is down 1.18 percent to $2.09 in afternoon trading but is up 8 percent in the last month. The heart-drug maker has missed revenue forecasts for the last several quarters, most recently on Nov. 4. The next set of numbers are estimated for pre-market hours on March 3.
Overall option volume was 15 times greater than average, according to Heat Seeker. Calls outnumbered puts by a bullish 7-to-1 ratio.
By optionMONSTER Staff ([email protected])
November 30, 2015 3:25 PM
condep1002
30/11/15 17:44
Ha respondido al tema Farmas USA
Ir a respuesta
ampliación de la original
November 30, 2015 at 08:00 AM EST
Chiasma Announces Addition of James R. Tobin and John F. Thero to Board of Directors
NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that James R. Tobin and John F. Thero have joined the company's Board of Directors.
Mr. Tobin, formerly president and CEO of Biogen, Inc. and Boston Scientific Corporation, will serve as a member of the Audit Committee. Mr. Thero, President and CEO of Amarin Corporation (NASDAQ:AMRN), will serve as chairman of the Audit Committee.
"We are excited to add these experienced, highly regarded biotech leaders to Chiasma's Board of Directors at this important stage in our development," said Mark Leuchtenberger, Chief Executive Officer of Chiasma. "Both Jim and John have deep operational and commercial experience on an international level, and their business acumen and leadership will be invaluable to the Board as we continue to build out our infrastructure and position the company for long-term success."
Mr. Tobin was most recently President and CEO of Boston Scientific Corporation from March 1999 to July 2009. Prior to Boston Scientific, he served as President and CEO of Biogen from February 1997 to December 1998, and President and COO of Biogen from February 1994 to February 1997. Prior to joining Biogen, Mr. Tobin was with Baxter International Inc., where he served as President and COO from 1992 to 1994, as Executive Vice President from 1988 to 1992, and in various management positions prior to 1988. Mr. Tobin served as lieutenant in the U.S. Navy from 1968 to 1972. He has been a Director of multiple private and public life science firms and hospitals, and currently serves on the boards of several private companies as well as Globus Medical, Inc. (NYSE:GMED) and Oxford Immunotec Global PLC (NASDAQ:OXFD). Mr. Tobin earned an M.B.A. from Harvard Business School and an A.B. from Harvard College.
Mr. Thero joined Amarin in November 2009 and has more than 20 years of senior financial and operational management experience, including more than 15 years supporting the growth of life science companies. Mr. Thero became President and CEO of Amarin in 2014 after previously serving as the company's President and initially as the company's Chief Financial Officer. Prior to Amarin, Mr. Thero was at ViaCell, Inc., where as Chief Financial Officer he helped guide the company to its successful sale to PerkinElmer, and Abiomed, Inc., where he held multiple positions, including Senior Vice President of Business Operations and Chief Financial Officer, and helped manage the company's transition from a development-stage company into a commercial entity. Mr. Thero began his professional career at Arthur Andersen LLP.